Protocol Ledger

NCT07687186 · Phase III · RECRUITING

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre

Interventional Phase III clinical trial protocol NCT07687186 sponsored by Tasly Pharmaceutical Group Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-21 Enrollment: 636 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07687186
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)636 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07687186
Protocol FieldVerified Registry Value
NCT IdentifierNCT07687186
Consolidated Lead SponsorTasly Pharmaceutical Group Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment636 participants (ESTIMATED)
Registered Start Date2026-08-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07687186
Hospital Research SiteLocationSite Profile
Liuzhou People's HospitalLiuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI